The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory
Abstract
FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride) prolongs survival of solid organ allografts in animal models. Mechanisms of FTY720 immunomodulation were studied in mice infected with lymphocytic choriomeningitis virus (LCMV) to assess T cell responses or with vesicular stomatitis virus to evaluate Ab responses. Oral FTY720 (0.3 mg/kg/day) did not affect LCMV replication and specific CTL and B cells were induced and expanded normally. Moreover, the anti-viral humoral immune responses were normal. However, FTY720 treatment showed first a shift of overall distribution of CTL from the spleen to peripheral lymph nodes and lymphocytopenia was observed. This effect was reversible within 7–21 days. Together with unimpaired T and B cell memory after FTY720 treatment, this finding rendered enhancement of lymphocyte apoptosis by FTY720 in vivo unlikely. Secondly, the delayed-type hypersensitivity reaction to a viral MHC class I-presented peptide was markedly reduced by FTY720. These results were supported by impaired circulation of LCMV specific TCR transgenic effector lymphocytes in the peripheral blood and reduced numbers of tissue infiltrating CTL in response to delayed-type hypersensitivity reaction. Thirdly, in a CD8+ T cell-mediated diabetes model in a transgenic mouse expressing the LCMV glycoprotein in the islets of the pancreas, FTY720 delayed or prevented disease by reducing islet-infiltrating CTL. Thus, FTY720 effectively reduced recirculation of CD8+ effector T cells and their recruitment to peripheral lesions without affecting the induction and expansion of immune responses in secondary lymphoid organs. These properties may offer the potential to treat ongoing organ-specific T cell-mediated immunopathologic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zinkernagel, R. M., & Doherty, P. C. (1979) · Advances in Immunology · doi:10.1016/s0065-2776(08)60262-x · Cited by 1,933
Self-citationOates, J. A., Wood, A. J. J., & Kahan, B. D. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912213212507 · Cited by 1,359
Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B., Zinkernagel, R. M., & Hengartner, H. (1991) · Cell · doi:10.1016/0092-8674(91)90164-t · Cited by 1,173
Self-citationTherapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
Massive Expansion of Antigen-Specific CD8+ T Cells during an Acute Virus Infection
Butz, E. A., & Bevan, M. J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80469-0 · Cited by 769
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
The Virology and Immunobiology of Lymphocytic Choriomeningitis Virus Infection
Buchmeier, M. J., Welsh, R. M., Dutko, F. J., & Oldstone, M. B. A. (1980) · Advances in Immunology · doi:10.1016/s0065-2776(08)60197-2 · Cited by 545
FUJITA, T., INOUE, K., YAMAMOTO, S., IKUMOTO, T., SASAKI, S., TOYAMA, R., CHIBA, K., HOSHINO, Y., & OKUMOTO, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 540
Battegay, M., Cooper, S., Althage, A., Bänziger, J., Hengartner, H., & Zinkernagel, R. M. (1991) · Journal of Virological Methods · doi:10.1016/0166-0934(91)90018-u · Cited by 475
Self-citation
Cited by
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Self-citationHoming and cellular traffic in lymph nodes
von Andrian, U. H., & Mempel, T. R. (2003) · Nature Reviews Immunology · doi:10.1038/nri1222 · Cited by 1,281
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citationOral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
“This has significant implications because peripheral TEMs (ie, in gut epithelial surfaces, small intestine lamina propria, lung, liver, kidney, peritoneum, bone marrow, and blood) are thought to be involved in the rapid containment of locally invading pathogens(77) and may be important for immune surveillance and memo…”
BackgroundInfluentialSphingosine 1-phosphate and its receptors: an autocrine and paracrine network
Rosen, H., & Goetzl, E. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1650 · Cited by 694
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Self-citationBrinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Self-citationBrinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438
Self-citationPhosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone
Cinamon, G., Matloubian, M., Lesneski, M. J., Xu, Y., Low, C., Lu, T., Proia, R. L., & Cyster, J. G. (2004) · Nature Immunology · doi:10.1038/ni1083 · Cited by 418
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Self-citationForrest, M., Sun, S.-Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062828 · Cited by 333
Lo, C. G., Xu, Y., Proia, R. L., & Cyster, J. G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041509 · Cited by 319
Sphingolipids in inflammation: pathological implications and potential therapeutic targets
Nixon, G. F. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00281.x · Cited by 285
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Sphingosine Kinase: Biochemical and Cellular Regulation and Role in Disease
Taha, T. A., Hannun, Y. A., & Obeid, L. M. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.2.113 · Cited by 276
CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes
Chakravarty, S., Cockburn, I. A., Kuk, S., Overstreet, M. G., Sacci, J. B., & Zavala, F. (2007) · Nature Medicine · doi:10.1038/nm1628 · Cited by 275
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341073 · Cited by 270
Brinkmann, V., & Lynch, K. R. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00374-6 · Cited by 262
Self-citationIdzko, M., Hammad, H., Nimwegen, M. V., Kool, M., Müller, T., Soullié, T., Willart, M. A. M., Hijdra, D., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28295 · Cited by 258
Liu, L., Zhong, Q., Tian, T., Dubin, K., Athale, S. K., & Kupper, T. S. (2010) · Nature Medicine · doi:10.1038/nm.2078 · Cited by 252
Marsolais, D., Hahm, B., Walsh, K. B., Edelmann, K. H., McGavern, D., Hatta, Y., Kawaoka, Y., Rosen, H., & Oldstone, M. B. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812689106 · Cited by 122
Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
Potenza, R. L., De Simone, R., Armida, M., Mazziotti, V., Pèzzola, A., Popoli, P., & Minghetti, L. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0462-2 · Cited by 69
Maki, T., Gottschalk, R., Ogawa, N., & Monaco, A. P. (2005) · Transplantation · doi:10.1097/01.tp.0000161220.87548.ee · Cited by 68
“FTY720 does not impair humoral immune responses or immunologic memory at both the T- and the B-cell levels and does not suppress the generation of primary virus-specific cytotoxic T lymphocytes in lymph nodes (4).”
Background
Metadata
- Authors
- Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-06-01
- Volume
- 164
- Issue
- 11
- Pages
- 5761-5770
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1654241956
- Cited by
- 365
- References
- 35
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.